Non-Hodgkin Lymphoma Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Non-Hodgkin Lymphoma Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The non-Hodgkin lymphoma therapeutics market is expected to register a CAGR of nearly 7.4% during the forecast period (2022-2027).

The COVID-19 pandemic has had some adverse impacts on market growth, as stated by the effects shown in various research studies. For instance, in August 2021, a research study published titled "A case report of COVID-19 in a patient with non-Hodgkin's lymphoma" stated that non-Hodgkin’s lymphoma presents a dilemma to healthcare professionals as there is concern that chemotherapeutic and immunosuppressive treatment, which is a pillar of cancer therapy, may lead to a worsening of comorbid COVID-19 infections. Similarly, another research study published in August 2021, titled "Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma," stated that patients diagnosed with B-cell non-Hodgkin's lymphoma (B-NHL), particularly if recently treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Effective vaccination against SARS-CoV-2 may help protect patients with lymphoma against COVID-19; however, the intrinsic immune deficiency associated with B-NHL, as well as the anti-lymphoma treatment itself, may hamper responsiveness to vaccinations. Such studies provide insight into the adverse impact of COVID-19 on non-Hodgkin lymphoma therapeutics market growth in the coming future.

Certain factors that are driving the market growth include a rise in the prevalence of non-Hodgkin lymphoma (NHL), demand for innovative drugs and novel technologies, and an increase in the number of Food and Drug Administration (FDA) approvals for NHL therapy drugs. In February 2021, a research study published titled "Epidemiology, pathology, and clinical features of DLBCL" stated that the most common NHL in Western countries is diffuse large B-cell lymphoma (DLBCL), accounting for around 31% of adult cases. Other common aggressive B-cell subtypes include Mantle Cell Lymphoma (MCL) (6% of cases) and BL (2% of cases). Among indolent B-cell NHL, FL accounts for 22% of cases in the Western world, followed by marginal zone lymphoma (MZL) (8% of cases), chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL) (6% of cases) and lymphoplasmacytic lymphoma (LPL) (1% of cases). Common T-cell lymphomas make up only 10–15% of NHL diagnoses and include peripheral T-cell lymphoma (PTCL) (6% of cases) and cutaneous T-cell lymphoma (CTCL) (4% of cases).

Moreover, product launches and approvals are other factors driving the growth of the market. For instance, in June 2021, Oncodesign, a French company, entered into a partnership with Covalab, CheMatech, and ABX-CRO to launch the DRIVE-MRT (Molecular RadioTherapy) solution, which can offer an entire drug discovery process specialized in targeted systemic radiotherapy. Such product launches will increase the innovative products in the market, which will increase the market's growth.

However, the high cost of NHL drugs and various complications associated with them are acting as major restraints for the non-Hodgkin lymphoma therapeutics market. Additionally, stringent regulatory guidelines are limiting the growth of the market.

Key Market TrendsThe Radiation Therapy Segment is Expected to Hold a Significant Market Share over the Forecast Period

Radiotherapy is the use of high-energy beams or particles to kill cancer cells, and it can be delivered from a source outside the body, i.e., external beam radiation, or internally, such as brachytherapy. Usually, radiation treatments are given five days per week for several weeks. Various initiatives by the key market players are one of the major factors responsible for the growth of the segment. For instance, in June 2020, Siemens, one of the leading providers of PET and SPECT equipment, expanded its facility in Germany. Siemens Healthineers is further expanding its AI portfolio in the field of clinical decision-making. The AI-Rad Companion family supports radiologists, radiation oncologists, radiotherapists, and medical physicists through automated post-processing of MRI, CT, and X-ray datasets, which is expected to drive the demand for radiotherapy among the patient population.

Many companies entered into a partnership to provide the radiopharmaceutical industry with a unique service solution for theranostic drug development. For instance, in July 2021, Oncodesign, Covalab, CheMatech, and ABX-CRO entered into a partnership to launch the DRIVE-MRT (Molecular Radiotherapy) solution, which will have all technologies related to the validation of targets, the generation, and optimization of vectors, and the radiochemistry and PET/SPECT imaging techniques. Likewise, in May 2021, United Imaging, a China-based company involved in medical imaging and radiotherapy equipment, launched its uAIFI Technology Platform for MR and uExcel Technology Platform for PET/CT at the China International Medical Equipment Fair (CMEF).

Similarly, in June 2021, Elekta's Elekta Harmony radiation therapy system secured United States Food and Drug Administration (FDA) 510(k) clearance, paving the way for United States clinics to harness the system to treat a comprehensive range of indications using the latest radiotherapy techniques. Harmony perfectly balances productivity and precision without compromise, making the system well-suited to address changing United States demographics and practice patterns. Such initiatives will drive the segment's growth in the near future.

Thus, owing to the abovementioned factors, the market segment is expected to show growth over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

Due to increasing technological advancements and the rising incidences of NHL in the United States, North America is expected to dominate the non-Hodgkin's lymphoma therapeutics market. Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. In March 2022, the American Cancer Society's estimates for non-Hodgkin's lymphoma are that about 80,470 people (44,120 males and 36,350 females) will be diagnosed with NHL. This includes both adults and children. About 20,250 people will die from this cancer (11,700 males and 8,550 females). Overall, the chance that an individual will develop NHL in their lifetime is about 1 in 42; for a woman, the risk is about 1 in 52. Thus, such an increase in the target population is likely to contribute to regional growth.

Various research studies have provided insight into the prevalence of non-Hodgkin's lymphoma in the region. For instance, in April 2020, a research study published in the United States National Library of Medicine titled "Non-Hodgkin's lymphoma: A review" stated that Lymphomas constitute the third most common neoplasm in the head and neck region arising from the lymphoreticular system. Malignant lymphomas are divided into Hodgkin's disease and non-Hodgkin's lymphoma (NHL). NHL comprises approximately 5% of head and neck malignancies and displays a wide range of clinical manifestations comparable to Hodgkin's disease. Hodgkin's and non-Hodgkin's lymphomas are seen in the head and neck region, but extranodal disease, with or without lymph node involvement, is more common among NHL patients. Such understandings could provide information specifically on the type and location of cancer, which would stimulate market growth by advancing the precise therapeutics approach against cancer.

Furthermore, several therapy approvals are another factor boosting the growth of the market. For instance, in May 2022, the United States Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel). It is a cell-based gene therapy used to treat adult patients with specific forms of large B-cell lymphoma who have relapsed or failed at least two other types of systemic therapy. The FDA has approved Breyanzi, a CAR-T cell therapy, as the third gene therapy for several non-Hodgkin's lymphomas, including diffuse large B-cell lymphoma.

Hence, with the growing awareness of the disease, increasing government initiatives, and an increase in the burden of the disease, the market is expected to grow over the forecast period.

Competitive Landscape

The non-Hodgkin lymphoma therapeutics market is highly competitive and consists of a few major players. Companies like AstraZeneca, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly and Co., F. Hoffmann La-Roche Ltd, and GlaxoSmithKline PLC hold substantial market shares in the non-Hodgkin lymphoma therapeutics market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.